Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1

Status

Completed 2

Sponsor Class

OTHER 3INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2Pancreatic Neoplasms 1Ovarian Neoplasms 1Gynecologic Cancer 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Trastuzumab 209Paclitaxel 187Fulvestrant 161Capecitabine 150Docetaxel 136Letrozole 127exemestane 92palbociclib 76Anastrozole 75Cyclophosphamide 71Lapatinib 69Gemcitabine 66Bevacizumab 66pertuzumab 61pembrolizumab 60ribociclib 59Carboplatin 59abemaciclib 53eribulin 48Doxorubicin 45Vinorelbine 41Everolimus 41Ado-Trastuzumab Emtansine 41Tamoxifen 40130-nm albumin-bound paclitaxel 34Injections 31trastuzumab deruxtecan 30Albumin-Bound Paclitaxel 26olaparib 24Alpelisib 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Breast Neoplasms × genexol-PM × Clear all
NCT00876486 2017-05-01

Evaluate the Efficacy and Safety of Genexol®-PM Compared to Genexol® in Recurrent or Metastatic Breast Cancer

Samyang Biopharmaceuticals Corporation

Phase 3 Completed
213 enrolled
Breast

Breast Neoplasms

NCT02064829 2016-03-25

TRIBECA

Sorrento Therapeutics, Inc.

Phase NA Completed
111 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡